Abstract 764P
Background
Tislelizumab is an investigational, humanized, IgG4 monoclonal antibody with high affinity and binding specificity for programmed cell death-1 (PD-1) emerging as promising investigational agents for the treatment of advanced cervical cancer. This phase II trial evaluated the combination of Tislelizumab plus definitive chemoradiotherapy in patients with recurrent and/or metastatic cervical cancer who relapsed after prior platinum-based therapy.
Methods
PILOT-2020-511 was a single-arm, phase 2 trial done at Fudan University Shanghai Cancer Center (Shanghai, China). Patients aged 18-70 years with recurrent and/or metastatic cervical cancer, with an ECOG performance status of 0-2, and adequate organ and bone marrow function were eligible for inclusion. Patients received concurrent radiotherapy (58-60 Gy in 28 fractions), chemotherapy (4-6 cycles of intravenous paclitaxel [135 mg/m2] and carboplatin [AUC=5]), and tislelizumab (200 mg intravenously every 3 weeks for up to 1 year, or until disease progression or unacceptable toxicity). The primary endpoint was the complete response rate at 3 months after radiotherapy by investigator assessment. Secondary endpoints were overall survival, progression-free survival, duration of response, quality of life (not reported here), and safety. The trial is registered with Chictr.org.cn, ChiCTR2000034748 and follow-up is ongoing.
Results
Between September 1, 2020, and December 25, 2022, 41 patients were enrolled. The median age was 58 years (IQR 52-67), 30 (73.2%) of 42 patients had lymphatic metastasis, and 11 (26.8%) patients were organic metastasis. 40 (97.6%) of 41 patients completed the planned chemoradiotherapy and 32 (78%) of 41 had a complete response. The 1-year overall survival was 66.8% and 1-year progression-free survival was 61.8%. The most common grade 3 or worse adverse event was lymphopenia. The most common immune-related adverse event was thyroid dysfunction.
Conclusions
Combining Tislelizumab with definitive chemoradiotherapy provided encouraging activity and acceptable toxicity in patients with recurrent and/or metastatic cervical cancer, and this regimen warrants further investigation.
Clinical trial identification
ChiCTR2000034748.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11